Skye Bioscience, Inc.

SKYEReported to SECin USCIK 0001516551Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 31. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 31
Form 4 lines at Skye Bioscience, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Schwab Andrew J.—Open-market sell$7,2904,528 sharesSep 24, 2026Schwab Andrew J.$7,290Sell · Sep 24Open-market sell4,528Sep 24, 2026
Schwab Andrew J.—Open-market sell$184,910114,851 sharesSep 24, 2026Schwab Andrew J.$184,910Sell · Sep 24Open-market sell114,851Sep 24, 2026
Schwab Andrew J.—Open-market sell$1,7951,088 sharesSep 24, 2026Schwab Andrew J.$1,795Sell · Sep 24Open-market sell1,088Sep 24, 2026
Schwab Andrew J.—Open-market sell$45,56027,612 sharesSep 24, 2026Schwab Andrew J.$45,560Sell · Sep 24Open-market sell27,612Sep 24, 2026
5AM Partners VII, LLC—Open-market sell$7,2904,528 sharesSep 24, 20265AM Partners VII, LLC$7,290Sell · Sep 24Open-market sell4,528Sep 24, 2026